Skip to main content

Advertisement

SpringerLink
Log in

Patients with malignant hematological disorders treated on a palliative care unit: prognostic impact of clinical factors

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

A reliable estimation of prognosis in patients receiving palliative care is desirable in order to facilitate clinical decision finding. For patients with advanced hematological malignancies, only few data are available to estimate prognosis of the individual's remaining life span. Here, we sought to investigate potential clinical prognostic parameters in patients with hematological malignancies admitted to a palliative care unit. Using a prospectively collected database, we analyzed clinical and laboratory parameters regarding their prognostic impact in 290 patients with malignant hematological diseases. The parameters included patient-related factors such as Eastern Cooperative Oncology Group (ECOG) performance status, need for transfusions, parenteral nutrition or analgetics, and laboratory values (hemoglobin, platelet count, lactic dehydrogenase (LDH), albumin, total protein, calcium, and C-reactive protein (CRP)) as well as referral symptoms (including anemia, infection, fever, fatigue, and dyspnea). In univariate analyses, LDH (>248 U/l), albumin corrected calcium (>2.55 mmol/l), CRP (>50 mg/l), albumin (<30 g/l), platelet count (<90 × 109/l), total protein (≤60 g/l), hemoglobin (<10 g/dl), opioid treatment, performance status (ECOG >2), and need for parenteral nutrition or blood transfusion significantly correlated with impaired survival. Multivariate analysis showed that low performance status, low platelet count, opioid based pain therapy, high LDH, and low albumin were associated with poor prognosis. Using these five parameters, patients were divided into three “risk groups”: low risk (presence of zero to one factor), intermediate risk (two to three factors), and high risk. Median survival for the poor risk patients was 10 days, and the intermediate and low risk patients survived a median of 63 and 440 days, respectively (p < 0.0001). Several clinical and laboratory parameters were associated with a poor prognosis of patients with hematological malignancies treated on a palliative care unit. These parameters might help clinicians to estimate prognosis of remaining life span and individualize treatment and/or end-of-life care options for patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Howell DA, Shellens R, Roman E, Garry AC, Patmore R, Howard MR (2011) Haematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. Palliat Med 25(6):630–41

    Article  PubMed  Google Scholar 

  2. Manitta VJ, Philip JA, Cole-Sinclair MF (2010) Palliative care and the hemato-oncological patient: can we live together? A review of the literature. J Palliat Med 13(8):1021–5

    Article  PubMed  Google Scholar 

  3. Fadul NA, El Osta B, Dalal S, Poulter VA, Bruera E (2008) Comparison of symptom burden among patients referred to palliative care with hematologic malignancies versus those with solid tumors. J Palliat Med 11(3):422–7

    Article  PubMed  Google Scholar 

  4. Fadul N, Elsayem A, Palmer JL, Zhang T, Braiteh F, Bruera E (2007) Predictors of access to palliative care services among patients who died at a Comprehensive Cancer Center. J Palliat Med 10(5):1146–52

    Article  PubMed  Google Scholar 

  5. Cheng WW, Willey J, Palmer JL, Zhang T, Bruera E (2005) Interval between palliative care referral and death among patients treated at a comprehensive cancer center. J Palliat Med 8(5):1025–32

    Article  PubMed  Google Scholar 

  6. Ansell P, Howell D, Garry A, Kite S, Munro J, Roman E, Howard M (2007) What determines referral of UK patients with haematological malignancies to palliative care services? An exploratory study using hospital records. Palliat Med 21(6):487–92

    Article  PubMed  Google Scholar 

  7. Gripp S, Moeller S, Bölke E, Schmitt G, Matuschek C, Asgari S, Asgharzadeh F, Roth S, Budach W, Franz M, Willers R (2007) Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol 25(22):3313–20

    Article  PubMed  Google Scholar 

  8. Aabom B, Kragstrup J, Vondeling H, Bakketeig LS, Stovring H (2005) Defining cancer patients as being in the terminal phase: who receives a formal diagnosis, and what are the effects? J Clin Oncol 23(30):7411–6

    Article  CAS  PubMed  Google Scholar 

  9. Christakis NA, Lamont EB (2000) Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ 320(7233):469–72

    Article  CAS  PubMed  Google Scholar 

  10. Mack JW, Smith TJ (2012) Reasons why physicians do not have discussions about poor prognosis, why it matters, and what can be improved. J Clin Oncol 30(22):2715–7

    Article  PubMed  Google Scholar 

  11. Alt-Epping B, Wulf G, Nauck F (2011) Palliative care for patients with hematological malignancies—a case series. Ann Hematol 90(5):613–5

    Article  PubMed Central  PubMed  Google Scholar 

  12. Hill QA (2010) Intensify, resuscitate or palliate: decision making in the critically ill patient with haematological malignancy. Blood Rev 24(1):17–25

    Article  PubMed  Google Scholar 

  13. Pirovano M, Maltoni M, Nanni O, Marinari M, Indelli M, Zaninetta G, Petrella V, Barni S, Zecca E, Scarpi E, Labianca R, Amadori D, Luporini G (1999) A new palliative prognostic score: a first step for the standard of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. J Pain Symptom Manage 17(4):231–9

    Article  CAS  PubMed  Google Scholar 

  14. Maltoni M, Nanni O, Pirovano M, Scarpi E, Indelli M, Martini C, Monti M, Arnoldi E, Piva L, Ravaioli A, Cruciani G, Labianca R, Amadori D (1999) Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. J Pain Symptom Manage 17(4):240–7

    Article  CAS  PubMed  Google Scholar 

  15. Morita T, Tsunoda J, Inoue S, Chihara S (1999) The Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer 7(3):128–33

    Article  CAS  PubMed  Google Scholar 

  16. Scarpi E, Maltoni M, Miceli R, Mariani L, Caraceni A, Amadori D, Nanni O (2011) Survival prediction for terminally ill cancer patients: revision of Palliative Prognostic Score with incorporation of delirium. The Oncologist 16:1793–1799

    Article  PubMed  Google Scholar 

  17. Anderson F, Downing GM, Hill J, Casorso L, Lerch N (1996) Palliative Performance Scale (PPS): a new tool. J Palliat Care 12:5–11

    CAS  PubMed  Google Scholar 

  18. Lau F, Downing M, Lesperance M, Shaw J, Kuziemsky C (2006) Use of Palliative Performance Scale in end of life prognostication. J Palliat Med 9:1066–1075

    Article  PubMed  Google Scholar 

  19. Maltoni M, Scarpi E, Pittureri C, Martini F, Montanari L, Amaducci E, Derni S, Fabbri L, Rosati M, Amadori D, Nanni O (2012) Prospective comparison of prognostic scores in palliative care cancer populations. Oncologist 17(3):446–54

    Article  PubMed  Google Scholar 

Download references

Ethical standards

All procedures followed were in accordance with the ethical standards of the responsible committee.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. III. Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany

    M. Kripp, C. Schmidt, D. Gencer, D. Buchheidt, W.-K. Hofmann & R.-D. Hofheinz

  2. Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany

    L. R. Pilz

  3. Klinik für Innere Medizin II, Abt. Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Germany

    A. Hochhaus

  4. Masserberger Klinik Prof. Volhard - Prof. Georg Lenz, Masserberg, Germany

    A. Willer

Authors
  1. M. Kripp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Willer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. R. Pilz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Gencer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Buchheidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Hochhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W.-K. Hofmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R.-D. Hofheinz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Kripp.

Additional information

M. Kripp, A. Willer, and C. Schmidt contributed equally to the work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kripp, M., Willer, A., Schmidt, C. et al. Patients with malignant hematological disorders treated on a palliative care unit: prognostic impact of clinical factors. Ann Hematol 93, 317–325 (2014). https://doi.org/10.1007/s00277-013-1861-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-1861-7

Keywords

Search

Navigation